AstraZeneca’s (AZN) Sell Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft restated their sell rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report released on Wednesday,Digital Look reports. They currently have a £115 price target on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on AZN. Citigroup increased their price target on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Jefferies Financial Group reaffirmed a “buy” rating and issued a £175 price objective on shares of AstraZeneca in a research note on Monday, August 3rd. Finally, Berenberg Bank reiterated a “buy” rating and issued a £160 target price on shares of AstraZeneca in a report on Tuesday, July 28th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus target price of £152.17.

Get AstraZeneca alerts:

Check Out Our Latest Stock Report on AZN

AstraZeneca Stock Up 1.3%

Shares of LON:AZN opened at £122.40 on Wednesday. The firm has a market cap of £189.83 billion, a P/E ratio of 18.32, a P/E/G ratio of 0.86 and a beta of 0.21. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10. AstraZeneca has a 12-month low of £107.84 and a 12-month high of £157.32. The business has a fifty day simple moving average of £128.57 and a 200 day simple moving average of £138.20.

About AstraZeneca

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Read More

• Five stocks we like better than AstraZeneca
• Blueprint for a Boom: SEC Clears the Crypto Runway
• Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
• Advance Auto Parts Plunged, But Its Turnaround Is Still Working
• Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.